Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Active, not recruiting · NCT04592653 · Registry updated 2024-06-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) | neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2024-06-07 | NCT04592653 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Mural Oncology, Inc | 1 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| CIOCC HM Sanchinarro | Madrid | Spain | 1 |
| Hospital Clinico San Carlos | Madrid | Spain | 103 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| NEXT Virginia | Fairfax | United States | 83 |
| START Midwest | Grand Rapids | United States | 79 |
| START Mountain | West Valley City | United States | 5 |